U.S. markets closed
  • S&P 500

    3,970.99
    +22.27 (+0.56%)
     
  • Dow 30

    32,237.53
    +132.28 (+0.41%)
     
  • Nasdaq

    11,823.96
    +36.56 (+0.31%)
     
  • Russell 2000

    1,734.92
    +14.63 (+0.85%)
     
  • Crude Oil

    69.20
    -0.76 (-1.09%)
     
  • Gold

    1,981.00
    -14.90 (-0.75%)
     
  • Silver

    23.36
    +0.11 (+0.47%)
     
  • EUR/USD

    1.0763
    -0.0073 (-0.68%)
     
  • 10-Yr Bond

    3.3800
    -0.0260 (-0.76%)
     
  • GBP/USD

    1.2232
    -0.0057 (-0.46%)
     
  • USD/JPY

    130.6700
    -0.1190 (-0.09%)
     
  • Bitcoin USD

    27,609.01
    -17.21 (-0.06%)
     
  • CMC Crypto 200

    597.33
    -21.06 (-3.41%)
     
  • FTSE 100

    7,405.45
    -94.15 (-1.26%)
     
  • Nikkei 225

    27,385.25
    -34.36 (-0.13%)
     

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

Compass Therapeutics
Compass Therapeutics

Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET

Key Opinion Leader to Participate

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion.

Webinar Details:

Date:

May 04, 2022

Time:

8:00 a.m. ET

Webcast:

Registration Link

Replay availability:

A replay will be available on the Compass website for 6 months.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
Vered Bisker-Leib, President & Chief Operating Officer
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099